Pasar al contenido principal

CONSTRUCCIONES VACUNALES PEPTIDICAS MONO Y MULTIVALENTES CONTRA LA FIEBRE AFTOSA: PRODUCCION OPTIMIZADA Y ESTUDIOS DE ESTRUCTURA, ESTABILIDAD Y BIODISTRIBUCION

AGL2017-84097-C2-2-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSITAT POMPEU FABRA CCT

Resultados relacionados

Resultados totales (Incluyendo duplicados): 44
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Leveraging the Aggregated Protein Dye YAT2150 for Malaria Chemotherapy

  • Camarero-Hoyos, Claudia
  • Bouzón-Arnáiz, Inés
  • Avalos-Padilla, Yunuen|||0000-0003-4074-5624
  • Fallica, Antonino Nicolò|||0000-0003-1899-8414
  • Román-Álamo, Lucía
  • Ramírez Moreno, Miriam|||0000-0002-9823-319X
  • Portabella, Emma
  • Cuspinera, Ona
  • Currea-Ayala, Daniela
  • Orozco-Quer, Marc
  • Ribera, Maria
  • Siden-Kiamos, Inga|||0000-0003-1572-5840
  • Spanos, Lefteris
  • Iglesias, Valentin|||0000-0002-6133-0869
  • Crespo, Benigno
  • Viera, Sara|||0000-0002-2025-4804
  • Andreu Martínez, David|||0000-0002-6317-6666
  • Sulleiro, Elena|||0000-0002-9783-6060
  • Zarzuela, Francesc
  • Urtasun, Nerea|||0000-0003-1093-2269
  • Pérez-Torras, Sandra|||0000-0002-2785-5602
  • Pastor-Anglada, Marçal|||0000-0003-3712-1773
  • Arce, Elsa M.|||0000-0003-3757-5468
  • Muñoz-Torrero López-Ibarra, Diego|||0000-0002-8140-8555
  • Fernández Busquets, Xavier|||0000-0002-4622-9631
Background/Objectives : YAT2150 is a first-in-class antiplasmodial compound that has been recently proposed as a new interesting drug for malaria therapy. Methods/Results : The fluorescence of YAT2150 rapidly increases upon its entry into Plasmodium, a property that can be of use for the design of highly sensitive diagnostic approaches. YAT2150 blocks the in vitro development of the ookinete stage of Plasmodium and, when added to an infected blood meal, inhibits oocyst formation in the mosquito. Thus, the compound could possibly contribute to future transmission-blocking antimalarial strategies. Cell influx/efflux studies in Caco-2 cells suggest that YAT2150 is internalized by endocytosis and also through the OATP2B1 transporter, whereas its main export route would be via OSTα. YAT2150 has an overall favorable drug metabolism and pharmacokinetics profile, and its moderate cytotoxicity can be significantly reduced upon encapsulation in immunoliposomes, which leads to a dramatic increase in the drug selectivity index to values close to 1000. Although YAT2150 binds amyloid-forming peptides, its in vitro fluorescence emission is stronger upon association with peptides that form amorphous aggregates, suggesting that regions enriched in unstructured proteins are the preferential binding sites of the drug inside Plasmodium cells. The reduction of protein aggregation in the parasite after YAT2150 treatment, which has been suggested to be directly related to the drug's mode of action, is also observed following treatment with quinoline antimalarials like chloroquine and primaquine. Conclusions : Altogether, the data presented here indicate that YAT2150 can represent the spearhead of a new family of compounds for malaria diagnosis and therapy due to its presumed novel mode of action based on the interaction with functional protein aggregates in the pathogen.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Disrupting GPCR complexes with smart drug-like peptides

  • Gallo, María, 1989-
  • Defaus, Sira
  • Andreu Martínez, David
G protein-coupled receptors (GPCRs) are a superfamily of proteins classically described as monomeric transmembrane (TM) receptors. However, increasing evidence indicates that many GPCRs form higher-order assemblies made up of monomers pertaining to identical (homo) or to various (hetero) receptors. The formation and structure of these oligomers, their physiological role and possible therapeutic applications raise a variety of issues that are currently being actively explored. In this context, synthetic peptides derived from TM domains stand out as powerful tools that can be predictably targeted to disrupt GPCR oligomers, especially at the interface level, eventually impairing their action. However, despite such potential, TM-derived, GPCR-disrupting peptides often suffer from inadequate pharmacokinetic properties, such as low bioavailability, a short half-life or rapid clearance, which put into question their therapeutic relevance and promise. In this review, we provide a comprehensive overview of GPCR complexes, with an emphasis on current studies using GPCR-disrupting peptides mimicking TM domains involved in multimerization, and we also highlight recent strategies used to achieve drug-like versions of such TM peptide candidates for therapeutic application., Financial support from the Spanish Ministry of Economy and Innovation (AGL2017-84097-C2-2-R, FEDER funds) and from La Caixa Banking Foundation (HR17-00409 and CI18-0045) is acknowledged.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Immunogenicity of foot-and-mouth disease virus dendrimer peptides: need for a T-cell epitope and ability to elicit heterotypic responses

  • Cañas Arranz, Rodrigo
  • de León, Patricia
  • Defaus, Sira
  • Torres, Elisa
  • Forner, Mar, 1980-
  • Bustos, María J.
  • Andreu Martínez, David
  • Blanco, Esther
  • Sobrino, Francisco
An approach based on a dendrimer display of B- and T-cell epitopes relevant for antibody induction has been shown to be effective as a foot-and-mouth disease (FMD) vaccine. B2T dendrimers combining two copies of the major FMD virus (FMDV) type O B-cell epitope (capsid proteinVP1 (140-158)) covalently linked to a heterotypic T-cell epitope from non-structural protein 3A (21-35), henceforth B2T-3A, has previously been shown to elicit high neutralizing antibody (nAb) titers and IFN-γ-producing cells in both mice and pigs. Here, we provide evidence that the B- and T-cell epitopes need to be tethered to a single molecular platform for successful T-cell help, leading to efficient nAb induction in mice. In addition, mice immunized with a non-covalent mixture of B2T-3A dendrimers containing the B-cell epitopes of FMDV types O and C induced similarly high nAb levels against both serotypes, opening the way for a multivalent vaccine platform against a variety of serologically different FMDVs. These findings are relevant for the design of vaccine strategies based on B- and T-cell epitope combinations., This research was funded by the Spanish Ministry of Science, Innovation and Universities (grants AGL2014-48923-C2 and AGL2017-84097-C2-2-R (to D.A. and F.S), and PID2019-107145RB-100 (to E.B.)), as well as by Comunidad de Madrid co-financed ECFEDER funds (S2013/ABI-350 2906-PLATESA and P2018/BAA-4370 to F.S. and E.B.), and by Generalitat de Catalunya (2009SGR492 to D.A.). Work at Centro de Biología Molecular “Severo Ochoa” and at UPF was supported by the Fundación Ramón Areces and by the Maria de Maeztu Program of the Spanish Ministry of Science, Innovation and Universities, respectively. M.F. and R.C.-A. were holders of a PhD fellowship from the Spanish Ministry of Science, Innovation and Universities.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Peptide-based multiepitopic vaccine platforms via click reactions

  • Forner, Mar, 1980-
  • Defaus, Sira
  • Andreu Martínez, David
Multimeric antigen display and high overall valency are increasingly regarded as strategic goals for potent and broadly efficacious synthetic vaccines with potential market prospects. Herein, a modular and versatile approach to multifunctional peptide-based vaccine platforms at multimilligram scale in reasonable yields is reported. Preparation of chemoselectively modified peptide building blocks of medium-to-large size, conjugation of these subunits, and final assembly were achieved by a combination of Michael-type thiol-ene addition and copper(I)-mediated alkyne-azide cycloaddition. The size and structural complexity of the building blocks required exploration of a further level of orthogonality, namely furan/maleimide Diels-Alder chemistry. After process optimization, a finely tuned, stepwise click approach has emerged as a workable, on-demand strategy to create macromolecular therapeutic vaccine assemblies., The study was supported by the Spanish Ministry of Economy and Competitiveness (MINECO) grants AGL2013-48923-C2 and AGL2017-84097-C2-2-R (to D.A.) as well as the MINECO "María de Maeztu" Program for Units of Excellence in R&D.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Estimating peptide half‐life in serum from tunable, sequence‐related physicochemical properties

  • Cavaco, Marco
  • Valle, Javier
  • Flores, Isabel
  • Andreu Martínez, David
  • Castanho, Miguel A.R.B.
Proteolytic instability is a critical limitation for peptide-based products. Although significant efforts are devoted to stabilize sequences against proteases/peptidases in plasma/serum, such approaches tend to be rather empirical, unspecific, time-consuming, and frequently not cost-effective. A more rational and potentially rewarding alternative is to identify the chemical grounds of susceptibility to enzymatic degradation of peptides so that proteolytic resistance can be tuned by manipulation of key chemical properties. In this regard, we conducted a meta-analysis of literature published over the last decade reporting experimental data on the lifetimes of peptides exposed to proteolytic conditions. Our initial database contained 579 entries and was curated with regard to amino acid sequence, chemical modification, terminal half-life (t1/2 ) or other stability readouts, type of stability assay, and biological application of the study. Although the majority of entries in the database corresponded to (slightly or substantially) modified peptides, we chose to focus on unmodified ones, as we aimed to decipher intrinsic characteristics of peptide proteolytic susceptibility. Specifically, we developed a multivariable regression model to unravel those peptide properties with most impact on proteolytic stability and thus potential t1/2 predicting ability. Model validation was done by two different approaches. First, a library of peptides spanning a large interval of properties that modulate stability was synthesized and their t1/2 in human serum were experimentally determined. Second, the t1/2 of 21 selected peptides approved for clinical use or in clinical trials were recorded and matched with the model-estimated values. With both approaches, good correlation between experimental and predicted t1/2 data was observed., This research was supported by the Portuguese Fundação para a Ciência e a Tecnologia (FCT; grants PD/BD/128281/2017, PTDC/BBB‐NAN/1578/2014, PTDC/BIA‐VIR/29495/2017, UID/Multi/04349/2019, and PTDC/QUI‐NUC/30147/2017), the Spanish Ministry of Economy and Innovation (MINECO, grants AGL2014‐52395‐C2‐2‐R and AGL2017‐84097‐C2‐2‐R, and Maria de Maeztu Program for Centers of Excellence); the European Union H2020‐MSCA‐RISE‐2014 program (grant no. 828774), and the “La Caixa” Banking Foundation (grant HR17‐00409).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Peptide-based vaccines: foot-and-mouth disease virus, a paradigm in animal health

  • Forner, Mar, 1980-
  • Cañas Arranz, Rodrigo
  • Defaus, Sira
  • de León, Patricia
  • Rodríguez Pulido, Miguel
  • Ganges, Lliliane
  • Blanco, Esther
  • Sobrino, Francisco
  • Andreu Martínez, David
Vaccines are considered one of the greatest global health achievements, improving the welfare of society by saving lives and substantially reducing the burden of infectious diseases. However, few vaccines are fully effective, for reasons ranging from intrinsic limitations to more contingent shortcomings related, e.g., to cold chain transport, handling and storage. In this context, subunit vaccines where the essential antigenic traits (but not the entire pathogen) are presented in rationally designed fashion have emerged as an attractive alternative to conventional ones. In particular, this includes the option of fully synthetic peptide vaccines able to mimic well-defined B- and T-cell epitopes from the infectious agent and to induce protection against it. Although, in general, linear peptides have been associated to low immunogenicity and partial protection, there are several strategies to address such issues. In this review, we report the progress towards the development of peptide-based vaccines against foot-and-mouth disease (FMD) a highly transmissible, economically devastating animal disease. Starting from preliminary experiments using single linear B-cell epitopes, recent research has led to more complex and successful second-generation vaccines featuring peptide dendrimers containing multiple copies of B- and T-cell epitopes against FMD virus or classical swine fever virus (CSFV). The usefulness of this strategy to prevent other animal and human diseases is discussed., This research was funded by the European Commission (project H2020-FETOPEN-2018-2019-2020-01 n° 828774), by the Spanish Ministry of Science, Innovation and Universities, grants AGL2014-48923-C2 and AGL2017-84097-C2-2-R (to D.A. and F.S.), and AGL2016-349 76445-R (to E.B.), as well as by Comunidad de Madrid co-financed ECFEDER funds (S2013/ABI-350 2906-PLATESA and P2018/BAA-4370 to F.S. and E.B.), and by Generalitat de Catalunya (2009SGR492 to D.A.). Work at Centro de Biología Molecular “Severo Ochoa” and at UPF was supported by Fundación Ramón Areces and by the Maria de Maeztu Program of the Spanish Ministry of Science, Innovation and Universities, respectively. M.F. and R.C.-A. were holders of a PhD fellowship from the Spanish Ministry of Science, Innovation and Universities.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Designing functionally versatile, highly immunogenic peptide-based multiepitopic vaccines against foot-and-mouth disease virus

  • Defaus, Sira
  • Forner, Mar, 1980-
  • Cañas Arranz, Rodrigo
  • de León, Patricia
  • Bustos, María J.
  • Rodríguez Pulido, Miguel
  • Blanco, Esther
  • Sobrino, Francisco
  • Andreu Martínez, David
A broadly protective and biosafe vaccine against foot-and-mouth disease virus (FMDV) remains an unmet need in the animal health sector. We have previously reported solid protection against serotype O FMDV afforded by dendrimeric peptide structures harboring virus-specific B- and T-cell epitopes, and also shown such type of multivalent presentations to be advantageous over simple B-T-epitope linear juxtaposition. Chemically, our vaccine platforms are modular constructions readily made from specified B- and T-cell epitope precursor peptides that are conjugated in solution. With the aim of developing an improved version of our formulations to be used for on-demand vaccine applications, we evaluate in this study a novel design for epitope presentation to the immune system based on a multiple antigen peptide (MAP) containing six immunologically relevant motifs arranged in dendrimeric fashion (named B2T-TB2). Interestingly, two B2T units fused tail-to-tail into a single homodimer platform elicited higher B- and T-cell specific responses than former candidates, with immunization scores remaining stable even after 4 months. Moreover, this macromolecular assembly shows consistent immune response in swine, the natural FMDV host, at reduced dose. Thus, our versatile, immunogenic prototype can find application in the development of peptide-based vaccine candidates for various therapeutic uses using safer and more efficacious vaccination regimens., This research was funded by Spanish Ministry of Science, Innovation and Universities grants AGL2014-48923-C2 and AGL2017-84097-C2-2-R (to D.A. and F.S.), and AGL2016-349 76445-R to E.B., as well as by Comunidad de Madrid co-financed ECFEDER funds (S2013/ABI-350 2906-PLATESA and P2018/BAA-4370 to F.S. and E.B.), and by Generalitat de Catalunya (2009SGR492 to D.A.).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A2A receptor homodimer-disrupting sequence efficiently delivered by a protease-resistant, cyclic CPP vector

  • Gallo, María, 1989-
  • Navarro, Gemma
  • Franco, Rafael
  • Andreu Martínez, David
G-protein-coupled receptors associate into dimers/oligomers whose function is not well understood. One approach to investigate this issue is to challenge oligomerization by peptides replicating transmembrane domains and to study their effect on receptor functionality. The disruptor peptides are typically delivered by means of cell-penetrating vectors such as the human immunodeficiency virus (HIV) transcription trans-activation protein Tat. In this paper we report a cyclic, Tat-like peptide that significantly improves its linear analogue in targeting interreceptor sequences in the transmembrane space. The same cyclic Tat-like vector fused to a transmembrane region not involved in receptor oligomerization was totally ineffective. Besides higher efficacy, the cyclic version has enhanced proteolytic stability, as shown by trypsin digestion experiments., Work at Pompeu Fabra University supported by grants AGL2014-52395-C2 and AGL2017-84097-C2-2-R and by the “María de Maeztu” Program for Units of Excellence in R&D from the Spanish Ministry of Innovation and Competitiveness (MINECO). Work at University of Barcelona supported by grants from the U.S. Alzheimer’s Association (AARFD-17-503612), from MINECO (BFU2015-64405-R; it may include EU FEDER funds) and from the Spanish Ministry of Science, Innovation and Universities and Agencia Estatal de Investigación (#2019_RTI2018-094204-B-I00; it includes EU FEDER funds).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

In Vivo sustained release of peptide vaccine mediated by dendritic mesoporous silica nanocarriers

  • An, Weiteng, 1988-
  • Defaus, Sira
  • Andreu Martínez, David
  • Rivera Gil, Pilar, 1976-
Mesoporous silica nanoparticles have drawn increasing attention as promising candidates in vaccine delivery. Previous studies evaluating silica-based vaccine delivery systems concentrated largely on macromolecular antigens, such as inactivated whole viruses. In this study, we synthesized dendritic mesoporous silica nanoparticles (DMSNs), and we evaluated their effectiveness as delivery platforms for peptide-based subunit vaccines. We encapsulated and tested in vivo an earlier reported foot-and-mouth disease virus (FMDV) peptide vaccine (B2T). The B2T@DMSNs formulation contained the peptide vaccine and the DMSNs without further need of other compounds neither adjuvants nor emulsions. We measured in vitro a sustained release up to 930 h. B2T@DMSNs-57 and B2T@DMSNs-156 released 23.7% (135 µg) and 22.8% (132 µg) of the total B2T. The formation of a corona of serum proteins around the DMSNs increased the B2T release up to 61% (348 µg/mg) and 80% (464 µg/mg) for B2T@DMSNs-57 and B2T@DMSNs-156. In vitro results point out to a longer sustained release, assisted by the formation of a protein corona around DMSNs, compared to the reference formulation (i.e., B2T emulsified in Montanide). We further confirmed in vivo immunogenicity of B2T@DMSNs in a particle size-dependent manner. Since B2T@DMSNs elicited specific immune responses in mice with high IgG production like the reference B2T@Montanide™, self-adjuvant properties of the DMSNs could be ascribed. Our results display DMSNs as efficacious nanocarriers for peptide-based vaccine administration., This research was funded by Spanish Ministry of Science, Innovation and Universities (grants AGL2014-48923-C2 and AGL2017-84097-C2-2-R to DA) as well as by Generalitat de Catalunya (grant 2009SGR492 to DA).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Rationally modified antimicrobial peptides from the N-terminal domain of human RNase 3 show exceptional serum stability

  • Sandín, Daniel
  • Valle, Javier
  • Chaves-Arquero, Belén
  • Prats-Ejarque, Guillem
  • Larrosa, María Nieves
  • González-López, Juan José
  • Jiménez, María Ángeles
  • Boix, Ester
  • Andreu Martínez, David
  • Torrent Burgas, Marc
Multidrug resistance against conventional antibiotics poses an important threat to human health. In this context, antimicrobial peptides (AMPs) have been extensively studied for their antibacterial activity and promising results have been shown so far. However, AMPs tend to be rather vulnerable to protease degradation, which offsets their therapeutic appeal. Here, we demonstrate how replacing functional residues in the antimicrobial region of human RNase 3-also named eosinophil cationic protein-by non-natural amino acids increases stability in human serum. These changes were also shown to reduce the hemolytic effect of the peptides in general terms, whereas the antimicrobial activity was reasonably preserved. Digestion profiles enabled us to design new peptides with superior stability and lower toxicity that could become relevant candidates to reach clinical stages., This work was supported by the Spanish Ministerio de Ciencia, Innovación y Universidades: SAF2015-72518-EXP, SAF2017-82158-R and RYC-2012-09999 to M.T.; CTQ2017-84371-P to M.A.J.; AGL2014-52395-C2; AGL2017-84097-C2-2-R to D.A. and PID2019-106123GB-I00 to E.B. Additional financial support from the European Society for Clinical Microbiology and Infectious Disease, ESCMID 2016, to M.T., the Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya, 2019 LLAV 00029 to M.T. and 2016 PROD 00060 to E.B. The “María de Maeztu” Program for Units of Excellence in R&D from the Spanish Ministry of Innovation and Competitiveness (MINECO) for work at Pompeu Fabra University (D.A.) is acknowledged. This work was supported, in part, by the European Regional Development Fund ‘A Way to Achieve Europe’ [Spanish Network for Research in Infectious Diseases (Grant No. RD16/0016/0003)]. D.S. and B.C.-A. are recipients of pre-doctoral FPI scholarships (PRE2018-083243 and BES-2015-073383, respectively) from the Spanish Ministerio de Ciencia, Innovación y Universidades.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The protein aggregation inhibitor YAT2150 has potent antimalarial activity in Plasmodium falciparum in vitro cultures

  • Bouzón-Arnáiz, Inés
  • Avalos-Padilla, Yunuen
  • Biosca, Arnau
  • Caño-Prades, Omar
  • Román-Álamo, Lucía
  • Valle, Javier
  • Andreu Martínez, David
  • Moita, Diana
  • Prudêncio, Miguel
  • Arce, Elsa M.
  • Muñoz-Torrero, Diego
  • Fernàndez Busquets, Xavier
Background: By 2016, signs of emergence of Plasmodium falciparum resistance to artemisinin and partner drugs were detected in the Greater Mekong Subregion. Recently, the independent evolution of artemisinin resistance has also been reported in Africa and South America. This alarming scenario calls for the urgent development of new antimalarials with novel modes of action. We investigated the interference with protein aggregation, which is potentially toxic for the cell and occurs abundantly in all Plasmodium stages, as a hitherto unexplored drug target in the pathogen. Results: Attempts to exacerbate the P. falciparum proteome's propensity to aggregation by delivering endogenous aggregative peptides to in vitro cultures of this parasite did not significantly affect their growth. In contrast, protein aggregation inhibitors clearly reduced the pathogen's viability. One such compound, the bis(styrylpyridinium) salt YAT2150, exhibited potent antiplasmodial activity with an in vitro IC50 of 90 nM for chloroquine- and artemisinin-resistant lines, arresting asexual blood parasites at the trophozoite stage, as well as interfering with the development of both sexual and hepatic forms of Plasmodium. At its IC50, this compound is a powerful inhibitor of the aggregation of the model amyloid β peptide fragment 1-40, and it reduces the amount of aggregated proteins in P. falciparum cultures, suggesting that the underlying antimalarial mechanism consists in a generalized impairment of proteostasis in the pathogen. YAT2150 has an easy, rapid, and inexpensive synthesis, and because it fluoresces when it accumulates in its main localization in the Plasmodium cytosol, it is a theranostic agent. Conclusions: Inhibiting protein aggregation in Plasmodium significantly reduces the parasite's viability in vitro. Since YAT2150 belongs to a novel structural class of antiplasmodials with a mode of action that potentially targets multiple gene products, rapid evolution of resistance to this drug is unlikely to occur, making it a promising compound for the post-artemisinin era., This work was supported by grants (i) PCIN-2017-100, RTI2018-094579-B-I00 and PID2021-128325OB-I00 (XF-B), and SAF2017-82771-R and PID2020-118127RB-I00 (DM-T), funded by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033 for grants PID2021- and PID2020-), which for grants RTI2018-, PID2021-, and SAF2017- included FEDER funds; (ii) ERA-NET Cofund EURONANOMED (http://euronanomed.net/), grant number 2017-178 (XF-B); and (iii) Generalitat de Catalunya, Spain (http://agaur.gencat.cat/), grant numbers 2017-SGR-908 (XF-B) and 2017-SGR-106 (DM-T). Work at Pompeu Fabra University was supported by the “La Caixa” Banking Foundation (https://fundacionlacaixa.org/, grant HR17-00409), and by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D from the Spanish Ministry of Science, Innovation and Universities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Human albumin impairs amyloid β-peptide fibrillation through its C-terminus: from docking modeling to protection against neurotoxicity in alzheimer's disease

  • Picón-Pagès, Pol
  • Bonet Martínez, Jaume, 1982-
  • García-García, Javier, 1982-
  • Garcia-Buendia, Joan
  • Gutierrez, Daniela
  • Valle, Javier
  • Gómez-Casuso, Carmen E.S.
  • Sidelkivska, Valeriya
  • Alvarez, Alejandra
  • Perálvarez Marín, Alex
  • Suades, Albert
  • Fernàndez Busquets, Xavier
  • Andreu Martínez, David
  • Vicente García, Rubén, 1978-
  • Oliva Miguel, Baldomero
  • Muñoz López, Francisco José, 1964-
Alzheimer's disease (AD) is a neurodegenerative process characterized by the accumulation of extracellular deposits of amyloid β-peptide (Aβ), which induces neuronal death. Monomeric Aβ is not toxic but tends to aggregate into β-sheets that are neurotoxic. Therefore to prevent or delay AD onset and progression one of the main therapeutic approaches would be to impair Aβ assembly into oligomers and fibrils and to promote disaggregation of the preformed aggregate. Albumin is the most abundant protein in the cerebrospinal fluid and it was reported to bind Aβ impeding its aggregation. In a previous work we identified a 35-residue sequence of clusterin, a well-known protein that binds Aβ, that is highly similar to the C-terminus (CTerm) of albumin. In this work, the docking experiments show that the average binding free energy of the CTerm-Aβ1-42 simulations was significantly lower than that of the clusterin-Aβ1-42 binding, highlighting the possibility that the CTerm retains albumin's binding properties. To validate this observation, we performed in vitro structural analysis of soluble and aggregated 1 μM Aβ1-42 incubated with 5 μM CTerm, equimolar to the albumin concentration in the CSF. Reversed-phase chromatography and electron microscopy analysis demonstrated a reduction of Aβ1-42 aggregates when the CTerm was present. Furthermore, we treated a human neuroblastoma cell line with soluble and aggregated Aβ1-42 incubated with CTerm obtaining a significant protection against Aβ-induced neurotoxicity. These in silico and in vitro data suggest that the albumin CTerm is able to impair Aβ aggregation and to promote disassemble of Aβ aggregates protecting neurons., This work was supported by the Spanish Ministry of Economy and Business through grant Plan Estatal SAF2017-83372-R & SAF2014-52228-R (FEDER funds/UE) to FJM and RV; BIO2017-85329-R to BO; AGL2014-52395-C2 and AGL2017- 84097-C2-2-R to D.A.; MDM-2014-0370 through the “María de Maeztu” Programme for Units of Excellence in R&D to “Departament de Ciències Experimentals i de la Salut”; the Chilean Government through Fondecyt 11611065 and AFB170005 to AA, and REDES 180084 to AA and FJM; ISGlobal and IBEC are members of the CERCA Programme, Generalitat de Catalunya.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

vCPP2319 interacts with metastatic breast cancer extracellular vesicles (EVs) and transposes a human blood-brain barrier model

  • Oliveira, Filipa D.
  • Cavaco, Marco
  • Figueira, Tiago N.
  • Napoleão, Patrícia
  • Valle, Javier
  • Neves, Vera
  • Andreu Martínez, David
  • Castanho, Miguel A.R.B.
Brain metastases (BM) are frequently found in cancer patients and, though their precise incidence is difficult to estimate, there is evidence for a correlation between BM and specific primary cancers, such as lung, breast, and skin (melanoma). Among all these, breast cancer is the most frequently diagnosed among women and, in this case, BM cause a critical reduction of the overall survival (OS), especially in triple negative breast cancer (TNBC) patients. The main challenge of BM treatment is the impermeable nature of the blood-brain barrier (BBB), which shields the central nervous systems (CNS) from chemotherapeutic drugs. Extracellular vesicles (EVs) have been proposed as ideal natural drug carriers and these may exhibit some advantages over synthetic nanoparticles (NPs). In this work, we isolate breast cancer-derived EVs and study their ability to carry vCPP2319, a peptide with dual cell-penetration and anticancer activities. The selective cytotoxicity of anticancer peptide-loaded EVs towards breast cancer cells and their ability to translocate an in vitro BBB model are also addressed. Overall, it was possible to conclude that vCPP2319 naturally interacts with breast cancer-derived EVs, being retained at the surface of these vesicles. Moreover, the results revealed a cytotoxic activity for peptide-loaded EVs similar to that obtained with the peptide alone and the ability of peptide-loaded EVs to translocate an in vitro BBB model, which contrasts with the results obtained with the peptide alone. In conclusion, this work supports the use of EVs in the development of biological drug-delivery systems (DDS) capable of translocating the BBB., FDO and MC acknowledge FCT I.P. for fellowships PD/BD/135046/2017, PD/BD/128281/2017. FCT I.P. is also acknowledged for funding (Projects PTDC/BIA-BQM/5027/2020 and PTDC/BTM-MAT/2472/2021). Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) is also acknowledged for funding: call H2020-MSCA-RISE-2014, grant agreement 644167, 2015–2019. The project leading to these results have received funding from “la Caixa” Foundation (ID 100010434) and FCT, I.P under the agreement LCF/PR/HP21/52310015. Work at UPF was supported by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D (MDM-2014-0370) from the Spanish Ministry of Economy and Competitiveness (MINECO).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Effect of the aggregated protein dye YAT2150 on Leishmania parasite viability

  • Román-Álamo, Lucía
  • Avalos-Padilla, Yunuen
  • Bouzón-Arnáiz, Inés
  • Iglesias, Valentin
  • Fernández Lajo, Jorge
  • Monteiro, Juan M.
  • Rivas, Luis
  • Fisa, Roser
  • Riera, Cristina
  • Andreu Martínez, David
  • Pintado-Grima, Carlos
  • Ventura, Salvador
  • Arce, Elsa M.
  • Muñoz-Torrero, Diego
  • Fernàndez Busquets, Xavier
The problems associated with the drugs currently used to treat leishmaniasis, including resistance, toxicity, and the high cost of some formulations, call for the urgent identification of new therapeutic agents with novel modes of action. The aggregated protein dye YAT2150 has been found to be a potent antileishmanial compound, with a half-maximal inhibitory concentration (IC50) of approximately 0.5 µM against promastigote and amastigote stages of Leishmania infantum. The encapsulation in liposomes of YAT2150 significantly improved its in vitro IC50 to 0.37 and 0.19 µM in promastigotes and amastigotes, respectively, and increased the half-maximal cytotoxic concentration in human umbilical vein endothelial cells to >50 µM. YAT2150 became strongly fluorescent when binding intracellular protein deposits in Leishmania cells. This fluorescence pattern aligns with the proposed mode of action of this drug in the malaria parasite Plasmodium falciparum, the inhibition of protein aggregation. In Leishmania major, YAT2150 rapidly reduced ATP levels, suggesting an alternative antileishmanial mechanism. To the best of our knowledge, this first-in-class compound is the only one described so far having significant activity against both Plasmodium and Leishmania, thus being a potential drug for the treatment of co-infections of both parasites., This work was supported by grants (i) Fundació La Marató de TV3, Ref. 201811 (X.F.-B.); (ii) PID2021-128325OB-I00 (X.F.-B.) and PID2020-118127RB-I00 (D.M.-T.), funded by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033), which included ERDF funds; (iii) II Premis Innovació Campus Clínic 2022, Hospital Clínic de Barcelona (X.F.-B.); and (iv) Generalitat de Catalunya, Spain (http://agaur.gencat.cat/), grant numbers 2021-SGR-00635 (S.V.) and 2021-SGR-00357 (D.M.-T.). Work at Pompeu Fabra University was supported by “La Caixa” Banking Foundation (https://fundacionlacaixa.org/, grant HR17-00409) and by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D from the Spanish Ministry of Science, Innovation and Universities. Work at the Centro de Investigaciones Biológicas was supported by grants from MCIN Subdirección General de Redes y Centros de Investigación Cooperativa-FEDER RD16/0027/0010 and CSIC PIE 201620E038. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Examining topoisomers of a snake-venom-derived peptide for improved antimicrobial and antitumoral properties

  • Carrera-Aubesart, Adam
  • Defaus, Sira
  • Pérez-Peinado, Clara, 1991-
  • Sandín, Daniel
  • Torrent Burgas, Marc
  • Jiménez, M. Ángeles
  • Andreu Martínez, David
Ctn[15-34], the C-terminal section of crotalicidin (Ctn), a cathelicidin from a South American pit viper, is an antimicrobial and antitumoral peptide with remarkably longer stability in human serum than the parent Ctn. In this work, a set of topoisomers of both Ctn and Ctn[15-34], including the retro, enantio, and retroenantio versions, were synthesized and tested to investigate the structural requirements for activity. All topoisomers were as active as the cognate sequences against Gram-negative bacteria and tumor cells while slightly more toxic towards normal cells. More importantly, the enhanced serum stability of the D-amino-acid-containing versions suggests that such topoisomers must be preferentially considered as future antimicrobial and anticancer peptide leads., Financial support from the Spanish Ministry of Economy and Innovation (grant AGL2017-84097-C2-2-R), from the Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033 grants PID2020-113184RB-C22; PID2020-112821GB-I00 and PID2020-114627RB-I00; MCIN/AEI/10.13039/501100011033/FEDER PDC2021-121544-I00), from the EU (Next GenerationEU/PRTR) and from La Caixa Banking Foundation (HR17-00409) is acknowledged.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Antimicrobial peptides can generate tolerance by lag and interfere with antimicrobial therapy

  • Sandín, Daniel
  • Valle, Javier
  • Morata, Jordi
  • Andreu Martínez, David
  • Torrent Burgas, Marc
Antimicrobial peptides (AMPs) are widely distributed molecules secreted mostly by cells of the innate immune system to prevent bacterial proliferation at the site of infection. As with classic antibiotics, continued treatment with AMPs can create resistance in bacteria. However, whether AMPs can generate tolerance as an intermediate stage towards resistance is not known. Here, we show that the treatment of Escherichia coli with different AMPs induces tolerance by lag, particularly for those peptides that have internal targets. This tolerance can be detected as different morphological and physiological changes, which depend on the type of peptide molecule the bacterium has been exposed to. In addition, we show that AMP tolerance can also affect antibiotic treatment. The genomic sequencing of AMP-tolerant strains shows that different mutations alter membrane composition, DNA replication, and translation. Some of these mutations have also been observed in antibiotic-resistant strains, suggesting that AMP tolerance could be a relevant step in the development of antibiotic resistance. Monitoring AMP tolerance is relevant vis-á-vis the eventual therapeutic use of AMPs and because cross-tolerance might favor the emergence of resistance against conventional antibiotic treatments., Financial support from the Spanish Ministry of Economy and Innovation (PDC2021-121544-I00 funded by MCIN/AEI /10.13039/501100011033 and European Union Next GenerationEU/ PRTR to M.T.; project PID2020-114627RB-I00 funded by MCIN/ AEI /10.13039/501100011033 to M.T. and AGL2017-84097-C2-2-R to D.A.), and from La Caixa Banking Foundation (HR17-00409, to D.A.). Work at UPF was funded by the MCI María de Maeztu network of Units of Excellence. D.S. is recipient of pre-doctoral a FPI scholarship (PRE2018-083243) from the Spanish Ministerio de Ciencia e Innovación.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The antimetastatic breast cancer activity of the viral protein-derived peptide vCPP2319 as revealed by cellular biomechanics

  • Oliveira, Filipa D.
  • Cavaco, Marco
  • Figueira, Tiago N.
  • Valle, Javier
  • Neves, Vera
  • Andreu Martínez, David
  • Gaspar, Diana
  • Castanho, Miguel A.R.B.
The incidence of metastatic breast cancer (MBC) is increasing and the therapeutic arsenal available to fight it is insufficient. Brain metastases, in particular, represent a major challenge for chemotherapy as the impermeable nature of the blood-brain barrier (BBB) prevents most drugs from targeting cells in the brain. For their ability to transpose biological membranes and transport a broad spectrum of bioactive cargoes, cell-penetrating peptides (CPPs) have been hailed as ideal candidates to deliver drugs across biological barriers. A more ambitious approach is to have the CPP as a drug itself, capable of both killing cancer cells and interacting with the blood/brain interface, therefore blocking the onset of brain metastases. vCPP2319, a viral protein-derived CPP, has both properties as it: (a) is selective toward human breast cancer cells (MDA-MB-231) and increases cell stiffness compared to breast epithelial cells (MCF 10A) hindering the progression of metastases; and (b) adsorbs at the surface of human brain endothelial cells potentially counteracting metastatic cells from reaching the brain. Overall, the results reveal the selective anticancer activity of the peptide vCPP2319, which is also able to reside at the blood-brain interface, therefore counteracting brain penetration by metastatic cancer cells., FDO, MC, and DG acknowledge FCT I.P. for fellowships PD/BD/135046/2017, PD/BD/128281/2017, and SFRH/ BPD/73500/2010. FCT I.P. is also acknowledged for funding (Projects PTDC/BIA-BQM/5027/2020 and PTDC/BBB-NAN/1578/2014). Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) is also acknowledged for funding: call H2020-MSCA-RISE-2014, grant agreement 644167, 2015–2019. Work at UPF was supported by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D (MDM-2014-0370) from the Spanish Ministry of Economy and Competitiveness (MINECO).
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Peptide-Based Vaccines: Foot-and-Mouth Disease Virus, a Paradigm in Animal Health

  • Forner, Mar
  • Cañas-Arranz, Rodrigo
  • Defaus, Sira
  • de León, Patricia
  • Rodríguez-Pulido, Miguel
  • Ganges, Llilianne
  • Blanco, Esther
  • Sobrino, Francisco
  • Andreu, David
Vaccines are considered one of the greatest global health achievements, improving the welfare of society by saving lives and substantially reducing the burden of infectious diseases. However, few vaccines are fully effective, for reasons ranging from intrinsic limitations to more contingent shortcomings related, e.g., to cold chain transport, handling and storage. In this context, subunit vaccines where the essential antigenic traits (but not the entire pathogen) are presented in rationally designed fashion have emerged as an attractive alternative to conventional ones. In particular, this includes the option of fully synthetic peptide vaccines able to mimic well-defined B- and T-cell epitopes from the infectious agent and to induce protection against it. Although, in general, linear peptides have been associated to low immunogenicity and partial protection, there are several strategies to address such issues. In this review, we report the progress towards the development of peptide-based vaccines against foot-and-mouth disease (FMD) a highly transmissible, economically devastating animal disease. Starting from preliminary experiments using single linear B-cell epitopes, recent research has led to more complex and successful second-generation vaccines featuring peptide dendrimers containing multiple copies of B- and T-cell epitopes against FMD virus or classical swine fever virus (CSFV). The usefulness of this strategy to prevent other animal and human diseases is discussed., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación

Designing functionally versatile, highly immunogenic peptide-based multiepitopic vaccines against foot-and-mouth disease Virus

  • Defaus, Sira
  • Forner, Mar
  • Cañas-Arranz, Rodrigo
  • León, Patricia de
  • Bustos, Maria José
  • Rodríguez Pulido, Miguel Ramón
  • Blanco Lavilla, Esther
  • Sobrino Castelló, Francisco
  • Andreu, David
A broadly protective and biosafe vaccine against foot-and-mouth disease virus (FMDV) remains an unmet need in the animal health sector. We have previously reported solid protection against serotype O FMDV afforded by dendrimeric peptide structures harboring virus-specific B- and T-cell epitopes, and also shown such type of multivalent presentations to be advantageous over simple B-T-epitope linear juxtaposition. Chemically, our vaccine platforms are modular constructions readily made from specified B- and T-cell epitope precursor peptides that are conjugated in solution. With the aim of developing an improved version of our formulations to be used for on-demand vaccine applications, we evaluate in this study a novel design for epitope presentation to the immune system based on a multiple antigen peptide (MAP) containing six immunologically relevant motifs arranged in dendrimeric fashion (named B<sub>2</sub>T-TB<sub>2</sub>). Interestingly, two B<sub>2</sub>T units fused tail-to-tail into a single homodimer platform elicited higher B- and T-cell specific responses than former candidates, with immunization scores remaining stable even after 4 months. Moreover, this macromolecular assembly shows consistent immune response in swine, the natural FMDV host, at reduced dose. Thus, our versatile, immunogenic prototype can find application in the development of peptide-based vaccine candidates for various therapeutic uses using safer and more efficacious vaccination regimens., This research was funded by Spanish Ministry of Science, Innovation and Universities grants AGL2014-48923-C2 and AGL2017-84097-C2-2-R (to D.A. and F.S.), and AGL2016-349 76445-R to E.B., as well as by Comunidad de Madrid co-financed ECFEDER funds (S2013/ABI-350 2906-PLATESA and P2018/BAA-4370 to F.S. and E.B.), and by Generalitat de Catalunya (2009SGR492 to D.A.). Work at Centro de Biología Molecular “Severo Ochoa” and at UPF was supported by Fundación Ramón Areces and by the Maria de Maeztu Program of the Spanish Ministry of Science, Innovation and Universities, respectively. R.C.-A. and M.F. were holders of a PhD fellowship from the Spanish Ministry of Science, Innovation and Universities (FPI program)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Rationally Modified Antimicrobial Peptides from the N-Terminal Domain of Human RNase 3 Show Exceptional Serum Stability

  • Sandín, Daniel
  • Valle, Javier
  • Chaves-Arquero, Belén
  • Prats-Ejarque, Guillem
  • Larrosa, M. N.
  • González-López, Juan J.
  • Jiménez, M. Angeles
  • Boix, Ester
  • Andreu, David
  • Torrent, Marc
11 pags., 6 figs., 5 tabs., Multidrug resistance against conventional antibiotics poses an important threat to human health. In this context, antimicrobial peptides (AMPs) have been extensively studied for their antibacterial activity and promising results have been shown so far. However, AMPs tend to be rather vulnerable to protease degradation, which offsets their therapeutic appeal. Here, we demonstrate how replacing functional residues in the antimicrobial region of human RNase 3 - also named eosinophil cationic protein - by non-natural amino acids increases stability in human serum. These changes were also shown to reduce the hemolytic effect of the peptides in general terms, whereas the antimicrobial activity was reasonably preserved. Digestion profiles enabled us to design new peptides with superior stability and lower toxicity that could become relevant candidates to reach clinical stages., This work was supported by the Spanish Ministerio de Ciencia, Innovacion y Universidades: SAF2015-72518-EXP, SAF2017- ́ 82158-R and RYC-2012-09999 to M.T.; CTQ2017-84371-P to M.A.J.; AGL2014-52395-C2; AGL2017-84097-C2-2-R to D.A. and PID2019-106123GB-I00 to E.B. Additional financial support from the European Society for Clinical Microbiology and Infectious Disease, ESCMID 2016, to M.T., the Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya, 2019 LLAV 00029 to M.T. and 2016 PROD 00060 to E.B. The “Marí a de Maeztu” Program for Units of Excellence in R&D from the Spanish Ministry of Innovation and Competitiveness (MINECO) for work at Pompeu Fabra University (D.A.) is acknowledged. This work was supported, in part, by the European Regional Development Fund ‘A Way to Achieve Europe’ [Spanish Network for Research in Infectious Diseases (Grant No. RD16/0016/0003)]. D.S. and B.C.-A. are recipients of pre-doctoral FPI scholarships (PRE2018-083243 and BES-2015-073383, respectively) from the Spanish Ministerio de Ciencia, Innovacion y Universidades.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Peptide-Based Vaccines: Foot-and-Mouth Disease Virus, a Paradigm in Animal Health

  • Forner, Mar
  • Cañas-Arranz, Rodrigo
  • Defaus, Sira
  • León, Patricia de
  • Rodríguez Pulido, Miguel Ramón
  • Ganges, Llilianne
  • Blanco Lavilla, Esther
  • Sobrino Castelló, Francisco
  • Andreu, David
Vaccines are considered one of the greatest global health achievements, improving the welfare of society by saving lives and substantially reducing the burden of infectious diseases. However, few vaccines are fully effective, for reasons ranging from intrinsic limitations to more contingent shortcomings related, e.g., to cold chain transport, handling and storage. In this context, subunit vaccines where the essential antigenic traits (but not the entire pathogen) are presented in rationally designed fashion have emerged as an attractive alternative to conventional ones. In particular, this includes the option of fully synthetic peptide vaccines able to mimic well-defined B- and T-cell epitopes from the infectious agent and to induce protection against it. Although, in general, linear peptides have been associated to low immunogenicity and partial protection, there are several strategies to address such issues. In this review, we report the progress towards the development of peptide-based vaccines against foot-and-mouth disease (FMD) a highly transmissible, economically devastating animal disease. Starting from preliminary experiments using single linear B-cell epitopes, recent research has led to more complex and successful second-generation vaccines featuring peptide dendrimers containing multiple copies of B- and T-cell epitopes against FMD virus or classical swine fever virus (CSFV). The usefulness of this strategy to prevent other animal and human diseases is discussed., European Commission (project H2020-FETOPEN-2018-2019-2020-01 n 828774), by the Spanish Ministry of Science, Innovation and Universities, grants AGL2014-48923-C2 and AGL2017-84097-C2-2-R (to D.A. and F.S.), and AGL2016-349 76445-R (to E.B.), as well as by Comunidad de Madrid co-financed ECFEDER funds (S2013/ABI-350 2906-PLATESA and P2018/BAA-4370 to F.S. and E.B.), and by Generalitat de Catalunya (2009SGR492 to D.A.). Work at Centro de Biología Molecular “Severo Ochoa” and at UPF was supported by Fundación Ramón Areces and by the Maria de Maeztu Program of the Spanish Ministry of Science, Innovation and Universities, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The protein aggregation inhibitor YAT2150 has potent antimalarial activity in Plasmodium falciparum in vitro cultures

  • Bouzón-Arnáiz, I.
  • Avalos-Padilla, Y.
  • Biosca, A.
  • Caño-Prades, O.
  • Román-Álamo, L.
  • Valle, Javier
  • Andreu, David
  • Moita, D.
  • Prudêncio, M.
  • Arce, E. M.
  • Muñoz-Torrero, Diego
  • Fernàndez-Busquets, Xavier
Background: By 2016, signs of emergence of Plasmodium falciparum resistance to artemisinin and partner drugs were detected in the Greater Mekong Subregion. Recently, the independent evolution of artemisinin resistance has also been reported in Africa and South America. This alarming scenario calls for the urgent development of new antimalarials with novel modes of action. We investigated the interference with protein aggregation, which is potentially toxic for the cell and occurs abundantly in all Plasmodium stages, as a hitherto unexplored drug target in the pathogen. Results: Attempts to exacerbate the P. falciparum proteome’s propensity to aggregation by delivering endogenous aggregative peptides to in vitro cultures of this parasite did not significantly affect their growth. In contrast, protein aggregation inhibitors clearly reduced the pathogen’s viability. One such compound, the bis(styrylpyridinium) salt YAT2150, exhibited potent antiplasmodial activity with an in vitro IC of 90 nM for chloroquine- and artemisinin-resistant lines, arresting asexual blood parasites at the trophozoite stage, as well as interfering with the development of both sexual and hepatic forms of Plasmodium. At its IC, this compound is a powerful inhibitor of the aggregation of the model amyloid β peptide fragment 1-40, and it reduces the amount of aggregated proteins in P. falciparum cultures, suggesting that the underlying antimalarial mechanism consists in a generalized impairment of proteostasis in the pathogen. YAT2150 has an easy, rapid, and inexpensive synthesis, and because it fluoresces when it accumulates in its main localization in the Plasmodium cytosol, it is a theranostic agent. Conclusions: Inhibiting protein aggregation in Plasmodium significantly reduces the parasite’s viability in vitro. Since YAT2150 belongs to a novel structural class of antiplasmodials with a mode of action that potentially targets multiple gene products, rapid evolution of resistance to this drug is unlikely to occur, making it a promising compound for the post-artemisinin era., This work was supported by grants (i) PCIN-2017-100, RTI2018-094579-B-I00 and PID2021-128325OB-I00 (XF-B), and SAF2017-82771-R and PID2020-118127RB-I00 (DM-T), funded by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033 for grants PID2021- and PID2020-), which for grants RTI2018-, PID2021-, and SAF2017- included FEDER funds; (ii) ERA-NET Cofund EURONANOMED (http://euronanomed.net/), grant number 2017-178 (XF-B); and (iii) Generalitat de Catalunya, Spain (http://agaur.gencat.cat/), grant numbers 2017-SGR-908 (XF-B) and 2017-SGR-106 (DM-T). Work at Pompeu Fabra University was supported by the “La Caixa” Banking Foundation (https://fundacionlacaixa.org/, grant HR17-00409), and by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D from the Spanish Ministry of Science, Innovation and Universities.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Examining Topoisomers of a Snake-Venom-Derived Peptide for Improved Antimicrobial and Antitumoral Properties

  • Carrera-Aubesart, Adam
  • Defaus, Sira
  • Pérez-Peinado, Clara
  • Sandín, Daniel
  • Torrent, Marc
  • Jiménez, M. Angeles
  • Andreu, David
13 pags., 6 figs., 2 tabs. -- This article belongs to the Special Issue Peptides of Natural Origin as Leads for Drug Discovery: From Native Structures to Peptidomimetics, Peptide-Conjugates, and Peptide-Nanoparticles 2.0, Ctn[15-34], the C-terminal section of crotalicidin (Ctn), a cathelicidin from a South American pit viper, is an antimicrobial and antitumoral peptide with remarkably longer stability in human serum than the parent Ctn. In this work, a set of topoisomers of both Ctn and Ctn[15-34], including the retro, enantio, and retroenantio versions, were synthesized and tested to investigate the structural requirements for activity. All topoisomers were as active as the cognate sequences against Gram-negative bacteria and tumor cells while slightly more toxic towards normal cells. More importantly, the enhanced serum stability of the D-amino-acid-containing versions suggests that such topoisomers must be preferentially considered as future antimicrobial and anticancer peptide leads., Financial support from the Spanish Ministry of Economy and Innovation (grant AGL2017-84097-C2-2-R), from the Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033 grants PID2020-113184RB-C22; PID2020-112821GB-I00 and PID2020-114627RB-I00; MCIN/AEI/10.13039/501100011033/FEDER PDC2021-121544-I00), from the EU (Next GenerationEU/PRTR) and from La Caixa Banking Foundation (HR17-00409) is acknowledged., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Designing functionally versatile, highly immunogenic peptide-based multiepitopic vaccines against foot-and-mouth disease virus

  • Defaus, Sira
  • Forner, Mar, 1980-
  • Cañas Arranz, Rodrigo
  • de León, Patricia
  • Bustos, María J.
  • Rodríguez Pulido, Miguel
  • Blanco, Esther
  • Sobrino, Francisco
  • Andreu Martínez, David
A broadly protective and biosafe vaccine against foot-and-mouth disease virus (FMDV) remains an unmet need in the animal health sector. We have previously reported solid protection against serotype O FMDV afforded by dendrimeric peptide structures harboring virus-specific B- and T-cell epitopes, and also shown such type of multivalent presentations to be advantageous over simple B-T-epitope linear juxtaposition. Chemically, our vaccine platforms are modular constructions readily made from specified B- and T-cell epitope precursor peptides that are conjugated in solution. With the aim of developing an improved version of our formulations to be used for on-demand vaccine applications, we evaluate in this study a novel design for epitope presentation to the immune system based on a multiple antigen peptide (MAP) containing six immunologically relevant motifs arranged in dendrimeric fashion (named B2T-TB2). Interestingly, two B2T units fused tail-to-tail into a single homodimer platform elicited higher B- and T-cell specific responses than former candidates, with immunization scores remaining stable even after 4 months. Moreover, this macromolecular assembly shows consistent immune response in swine, the natural FMDV host, at reduced dose. Thus, our versatile, immunogenic prototype can find application in the development of peptide-based vaccine candidates for various therapeutic uses using safer and more efficacious vaccination regimens., This research was funded by Spanish Ministry of Science, Innovation and Universities grants AGL2014-48923-C2 and AGL2017-84097-C2-2-R (to D.A. and F.S.), and AGL2016-349 76445-R to E.B., as well as by Comunidad de Madrid co-financed ECFEDER funds (S2013/ABI-350 2906-PLATESA and P2018/BAA-4370 to F.S. and E.B.), and by Generalitat de Catalunya (2009SGR492 to D.A.).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The antimetastatic breast cancer activity of the viral protein-derived peptide vCPP2319 as revealed by cellular biomechanics

  • Oliveira, Filipa D.
  • Cavaco, Marco
  • Figueira, Tiago N.
  • Valle, Javier
  • Neves, Vera
  • Andreu Martínez, David
  • Gaspar, Diana
  • Castanho, Miguel A.R.B.
The incidence of metastatic breast cancer (MBC) is increasing and the therapeutic arsenal available to fight it is insufficient. Brain metastases, in particular, represent a major challenge for chemotherapy as the impermeable nature of the blood-brain barrier (BBB) prevents most drugs from targeting cells in the brain. For their ability to transpose biological membranes and transport a broad spectrum of bioactive cargoes, cell-penetrating peptides (CPPs) have been hailed as ideal candidates to deliver drugs across biological barriers. A more ambitious approach is to have the CPP as a drug itself, capable of both killing cancer cells and interacting with the blood/brain interface, therefore blocking the onset of brain metastases. vCPP2319, a viral protein-derived CPP, has both properties as it: (a) is selective toward human breast cancer cells (MDA-MB-231) and increases cell stiffness compared to breast epithelial cells (MCF 10A) hindering the progression of metastases; and (b) adsorbs at the surface of human brain endothelial cells potentially counteracting metastatic cells from reaching the brain. Overall, the results reveal the selective anticancer activity of the peptide vCPP2319, which is also able to reside at the blood-brain interface, therefore counteracting brain penetration by metastatic cancer cells., FDO, MC, and DG acknowledge FCT I.P. for fellowships PD/BD/135046/2017, PD/BD/128281/2017, and SFRH/ BPD/73500/2010. FCT I.P. is also acknowledged for funding (Projects PTDC/BIA-BQM/5027/2020 and PTDC/BBB-NAN/1578/2014). Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) is also acknowledged for funding: call H2020-MSCA-RISE-2014, grant agreement 644167, 2015–2019. Work at UPF was supported by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D (MDM-2014-0370) from the Spanish Ministry of Economy and Competitiveness (MINECO).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Disrupting GPCR complexes with smart drug-like peptides

  • Gallo, María, 1989-
  • Defaus, Sira
  • Andreu Martínez, David
G protein-coupled receptors (GPCRs) are a superfamily of proteins classically described as monomeric transmembrane (TM) receptors. However, increasing evidence indicates that many GPCRs form higher-order assemblies made up of monomers pertaining to identical (homo) or to various (hetero) receptors. The formation and structure of these oligomers, their physiological role and possible therapeutic applications raise a variety of issues that are currently being actively explored. In this context, synthetic peptides derived from TM domains stand out as powerful tools that can be predictably targeted to disrupt GPCR oligomers, especially at the interface level, eventually impairing their action. However, despite such potential, TM-derived, GPCR-disrupting peptides often suffer from inadequate pharmacokinetic properties, such as low bioavailability, a short half-life or rapid clearance, which put into question their therapeutic relevance and promise. In this review, we provide a comprehensive overview of GPCR complexes, with an emphasis on current studies using GPCR-disrupting peptides mimicking TM domains involved in multimerization, and we also highlight recent strategies used to achieve drug-like versions of such TM peptide candidates for therapeutic application., Financial support from the Spanish Ministry of Economy and Innovation (AGL2017-84097-C2-2-R, FEDER funds) and from La Caixa Banking Foundation (HR17-00409 and CI18-0045) is acknowledged.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Antimicrobial peptides can generate tolerance by lag and interfere with antimicrobial therapy

  • Sandín, Daniel
  • Valle, Javier
  • Morata, Jordi
  • Andreu Martínez, David
  • Torrent Burgas, Marc
Antimicrobial peptides (AMPs) are widely distributed molecules secreted mostly by cells of the innate immune system to prevent bacterial proliferation at the site of infection. As with classic antibiotics, continued treatment with AMPs can create resistance in bacteria. However, whether AMPs can generate tolerance as an intermediate stage towards resistance is not known. Here, we show that the treatment of Escherichia coli with different AMPs induces tolerance by lag, particularly for those peptides that have internal targets. This tolerance can be detected as different morphological and physiological changes, which depend on the type of peptide molecule the bacterium has been exposed to. In addition, we show that AMP tolerance can also affect antibiotic treatment. The genomic sequencing of AMP-tolerant strains shows that different mutations alter membrane composition, DNA replication, and translation. Some of these mutations have also been observed in antibiotic-resistant strains, suggesting that AMP tolerance could be a relevant step in the development of antibiotic resistance. Monitoring AMP tolerance is relevant vis-á-vis the eventual therapeutic use of AMPs and because cross-tolerance might favor the emergence of resistance against conventional antibiotic treatments., Financial support from the Spanish Ministry of Economy and Innovation (PDC2021-121544-I00 funded by MCIN/AEI /10.13039/501100011033 and European Union Next GenerationEU/ PRTR to M.T.; project PID2020-114627RB-I00 funded by MCIN/ AEI /10.13039/501100011033 to M.T. and AGL2017-84097-C2-2-R to D.A.), and from La Caixa Banking Foundation (HR17-00409, to D.A.). Work at UPF was funded by the MCI María de Maeztu network of Units of Excellence. D.S. is recipient of pre-doctoral a FPI scholarship (PRE2018-083243) from the Spanish Ministerio de Ciencia e Innovación.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Estimating peptide half‐life in serum from tunable, sequence‐related physicochemical properties

  • Cavaco, Marco
  • Valle, Javier
  • Flores, Isabel
  • Andreu Martínez, David
  • Castanho, Miguel A.R.B.
Proteolytic instability is a critical limitation for peptide-based products. Although significant efforts are devoted to stabilize sequences against proteases/peptidases in plasma/serum, such approaches tend to be rather empirical, unspecific, time-consuming, and frequently not cost-effective. A more rational and potentially rewarding alternative is to identify the chemical grounds of susceptibility to enzymatic degradation of peptides so that proteolytic resistance can be tuned by manipulation of key chemical properties. In this regard, we conducted a meta-analysis of literature published over the last decade reporting experimental data on the lifetimes of peptides exposed to proteolytic conditions. Our initial database contained 579 entries and was curated with regard to amino acid sequence, chemical modification, terminal half-life (t1/2 ) or other stability readouts, type of stability assay, and biological application of the study. Although the majority of entries in the database corresponded to (slightly or substantially) modified peptides, we chose to focus on unmodified ones, as we aimed to decipher intrinsic characteristics of peptide proteolytic susceptibility. Specifically, we developed a multivariable regression model to unravel those peptide properties with most impact on proteolytic stability and thus potential t1/2 predicting ability. Model validation was done by two different approaches. First, a library of peptides spanning a large interval of properties that modulate stability was synthesized and their t1/2 in human serum were experimentally determined. Second, the t1/2 of 21 selected peptides approved for clinical use or in clinical trials were recorded and matched with the model-estimated values. With both approaches, good correlation between experimental and predicted t1/2 data was observed., This research was supported by the Portuguese Fundação para a Ciência e a Tecnologia (FCT; grants PD/BD/128281/2017, PTDC/BBB‐NAN/1578/2014, PTDC/BIA‐VIR/29495/2017, UID/Multi/04349/2019, and PTDC/QUI‐NUC/30147/2017), the Spanish Ministry of Economy and Innovation (MINECO, grants AGL2014‐52395‐C2‐2‐R and AGL2017‐84097‐C2‐2‐R, and Maria de Maeztu Program for Centers of Excellence); the European Union H2020‐MSCA‐RISE‐2014 program (grant no. 828774), and the “La Caixa” Banking Foundation (grant HR17‐00409).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Peptide-Based Vaccines: Foot-and-Mouth Disease Virus, a Paradigm in Animal Health

  • Forner, Mar
  • Cañas-Arranz, Rodrigo
  • Defaus, Sira
  • de León, Patricia
  • Rodríguez-Pulido, Miguel
  • Ganges, Llilianne
  • Blanco, Esther
  • Sobrino, Francisco
  • Andreu, David
Vaccines are considered one of the greatest global health achievements, improving the welfare of society by saving lives and substantially reducing the burden of infectious diseases. However, few vaccines are fully effective, for reasons ranging from intrinsic limitations to more contingent shortcomings related, e.g., to cold chain transport, handling and storage. In this context, subunit vaccines where the essential antigenic traits (but not the entire pathogen) are presented in rationally designed fashion have emerged as an attractive alternative to conventional ones. In particular, this includes the option of fully synthetic peptide vaccines able to mimic well-defined B- and T-cell epitopes from the infectious agent and to induce protection against it. Although, in general, linear peptides have been associated to low immunogenicity and partial protection, there are several strategies to address such issues. In this review, we report the progress towards the development of peptide-based vaccines against foot-and-mouth disease (FMD) a highly transmissible, economically devastating animal disease. Starting from preliminary experiments using single linear B-cell epitopes, recent research has led to more complex and successful second-generation vaccines featuring peptide dendrimers containing multiple copies of B- and T-cell epitopes against FMD virus or classical swine fever virus (CSFV). The usefulness of this strategy to prevent other animal and human diseases is discussed., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Rationally modified antimicrobial peptides from the N-terminal domain of human RNase 3 show exceptional serum stability

  • Sandín, Daniel
  • Valle, Javier
  • Chaves-Arquero, Belén
  • Prats-Ejarque, Guillem
  • Larrosa, María Nieves
  • González-López, Juan José
  • Jiménez, María Ángeles
  • Boix, Ester
  • Andreu Martínez, David
  • Torrent Burgas, Marc
Multidrug resistance against conventional antibiotics poses an important threat to human health. In this context, antimicrobial peptides (AMPs) have been extensively studied for their antibacterial activity and promising results have been shown so far. However, AMPs tend to be rather vulnerable to protease degradation, which offsets their therapeutic appeal. Here, we demonstrate how replacing functional residues in the antimicrobial region of human RNase 3-also named eosinophil cationic protein-by non-natural amino acids increases stability in human serum. These changes were also shown to reduce the hemolytic effect of the peptides in general terms, whereas the antimicrobial activity was reasonably preserved. Digestion profiles enabled us to design new peptides with superior stability and lower toxicity that could become relevant candidates to reach clinical stages., This work was supported by the Spanish Ministerio de Ciencia, Innovación y Universidades: SAF2015-72518-EXP, SAF2017-82158-R and RYC-2012-09999 to M.T.; CTQ2017-84371-P to M.A.J.; AGL2014-52395-C2; AGL2017-84097-C2-2-R to D.A. and PID2019-106123GB-I00 to E.B. Additional financial support from the European Society for Clinical Microbiology and Infectious Disease, ESCMID 2016, to M.T., the Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya, 2019 LLAV 00029 to M.T. and 2016 PROD 00060 to E.B. The “María de Maeztu” Program for Units of Excellence in R&D from the Spanish Ministry of Innovation and Competitiveness (MINECO) for work at Pompeu Fabra University (D.A.) is acknowledged. This work was supported, in part, by the European Regional Development Fund ‘A Way to Achieve Europe’ [Spanish Network for Research in Infectious Diseases (Grant No. RD16/0016/0003)]. D.S. and B.C.-A. are recipients of pre-doctoral FPI scholarships (PRE2018-083243 and BES-2015-073383, respectively) from the Spanish Ministerio de Ciencia, Innovación y Universidades.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

vCPP2319 interacts with metastatic breast cancer extracellular vesicles (EVs) and transposes a human blood-brain barrier model

  • Oliveira, Filipa D.
  • Cavaco, Marco
  • Figueira, Tiago N.
  • Napoleão, Patrícia
  • Valle, Javier
  • Neves, Vera
  • Andreu Martínez, David
  • Castanho, Miguel A.R.B.
Brain metastases (BM) are frequently found in cancer patients and, though their precise incidence is difficult to estimate, there is evidence for a correlation between BM and specific primary cancers, such as lung, breast, and skin (melanoma). Among all these, breast cancer is the most frequently diagnosed among women and, in this case, BM cause a critical reduction of the overall survival (OS), especially in triple negative breast cancer (TNBC) patients. The main challenge of BM treatment is the impermeable nature of the blood-brain barrier (BBB), which shields the central nervous systems (CNS) from chemotherapeutic drugs. Extracellular vesicles (EVs) have been proposed as ideal natural drug carriers and these may exhibit some advantages over synthetic nanoparticles (NPs). In this work, we isolate breast cancer-derived EVs and study their ability to carry vCPP2319, a peptide with dual cell-penetration and anticancer activities. The selective cytotoxicity of anticancer peptide-loaded EVs towards breast cancer cells and their ability to translocate an in vitro BBB model are also addressed. Overall, it was possible to conclude that vCPP2319 naturally interacts with breast cancer-derived EVs, being retained at the surface of these vesicles. Moreover, the results revealed a cytotoxic activity for peptide-loaded EVs similar to that obtained with the peptide alone and the ability of peptide-loaded EVs to translocate an in vitro BBB model, which contrasts with the results obtained with the peptide alone. In conclusion, this work supports the use of EVs in the development of biological drug-delivery systems (DDS) capable of translocating the BBB., FDO and MC acknowledge FCT I.P. for fellowships PD/BD/135046/2017, PD/BD/128281/2017. FCT I.P. is also acknowledged for funding (Projects PTDC/BIA-BQM/5027/2020 and PTDC/BTM-MAT/2472/2021). Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) is also acknowledged for funding: call H2020-MSCA-RISE-2014, grant agreement 644167, 2015–2019. The project leading to these results have received funding from “la Caixa” Foundation (ID 100010434) and FCT, I.P under the agreement LCF/PR/HP21/52310015. Work at UPF was supported by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D (MDM-2014-0370) from the Spanish Ministry of Economy and Competitiveness (MINECO).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Peptide-based multiepitopic vaccine platforms via click reactions

  • Forner, Mar, 1980-
  • Defaus, Sira
  • Andreu Martínez, David
Multimeric antigen display and high overall valency are increasingly regarded as strategic goals for potent and broadly efficacious synthetic vaccines with potential market prospects. Herein, a modular and versatile approach to multifunctional peptide-based vaccine platforms at multimilligram scale in reasonable yields is reported. Preparation of chemoselectively modified peptide building blocks of medium-to-large size, conjugation of these subunits, and final assembly were achieved by a combination of Michael-type thiol-ene addition and copper(I)-mediated alkyne-azide cycloaddition. The size and structural complexity of the building blocks required exploration of a further level of orthogonality, namely furan/maleimide Diels-Alder chemistry. After process optimization, a finely tuned, stepwise click approach has emerged as a workable, on-demand strategy to create macromolecular therapeutic vaccine assemblies., The study was supported by the Spanish Ministry of Economy and Competitiveness (MINECO) grants AGL2013-48923-C2 and AGL2017-84097-C2-2-R (to D.A.) as well as the MINECO "María de Maeztu" Program for Units of Excellence in R&D.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

In Vivo sustained release of peptide vaccine mediated by dendritic mesoporous silica nanocarriers

  • An, Weiteng, 1988-
  • Defaus, Sira
  • Andreu Martínez, David
  • Rivera Gil, Pilar, 1976-
Mesoporous silica nanoparticles have drawn increasing attention as promising candidates in vaccine delivery. Previous studies evaluating silica-based vaccine delivery systems concentrated largely on macromolecular antigens, such as inactivated whole viruses. In this study, we synthesized dendritic mesoporous silica nanoparticles (DMSNs), and we evaluated their effectiveness as delivery platforms for peptide-based subunit vaccines. We encapsulated and tested in vivo an earlier reported foot-and-mouth disease virus (FMDV) peptide vaccine (B2T). The B2T@DMSNs formulation contained the peptide vaccine and the DMSNs without further need of other compounds neither adjuvants nor emulsions. We measured in vitro a sustained release up to 930 h. B2T@DMSNs-57 and B2T@DMSNs-156 released 23.7% (135 µg) and 22.8% (132 µg) of the total B2T. The formation of a corona of serum proteins around the DMSNs increased the B2T release up to 61% (348 µg/mg) and 80% (464 µg/mg) for B2T@DMSNs-57 and B2T@DMSNs-156. In vitro results point out to a longer sustained release, assisted by the formation of a protein corona around DMSNs, compared to the reference formulation (i.e., B2T emulsified in Montanide). We further confirmed in vivo immunogenicity of B2T@DMSNs in a particle size-dependent manner. Since B2T@DMSNs elicited specific immune responses in mice with high IgG production like the reference B2T@Montanide™, self-adjuvant properties of the DMSNs could be ascribed. Our results display DMSNs as efficacious nanocarriers for peptide-based vaccine administration., This research was funded by Spanish Ministry of Science, Innovation and Universities (grants AGL2014-48923-C2 and AGL2017-84097-C2-2-R to DA) as well as by Generalitat de Catalunya (grant 2009SGR492 to DA).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Human albumin impairs amyloid β-peptide fibrillation through its C-terminus: from docking modeling to protection against neurotoxicity in alzheimer's disease

  • Picón-Pagès, Pol
  • Bonet Martínez, Jaume, 1982-
  • García-García, Javier, 1982-
  • Garcia-Buendia, Joan
  • Gutierrez, Daniela
  • Valle, Javier
  • Gómez-Casuso, Carmen E.S.
  • Sidelkivska, Valeriya
  • Alvarez, Alejandra
  • Perálvarez Marín, Alex
  • Suades, Albert
  • Fernàndez Busquets, Xavier
  • Andreu Martínez, David
  • Vicente García, Rubén, 1978-
  • Oliva Miguel, Baldomero
  • Muñoz López, Francisco José, 1964-
Alzheimer's disease (AD) is a neurodegenerative process characterized by the accumulation of extracellular deposits of amyloid β-peptide (Aβ), which induces neuronal death. Monomeric Aβ is not toxic but tends to aggregate into β-sheets that are neurotoxic. Therefore to prevent or delay AD onset and progression one of the main therapeutic approaches would be to impair Aβ assembly into oligomers and fibrils and to promote disaggregation of the preformed aggregate. Albumin is the most abundant protein in the cerebrospinal fluid and it was reported to bind Aβ impeding its aggregation. In a previous work we identified a 35-residue sequence of clusterin, a well-known protein that binds Aβ, that is highly similar to the C-terminus (CTerm) of albumin. In this work, the docking experiments show that the average binding free energy of the CTerm-Aβ1-42 simulations was significantly lower than that of the clusterin-Aβ1-42 binding, highlighting the possibility that the CTerm retains albumin's binding properties. To validate this observation, we performed in vitro structural analysis of soluble and aggregated 1 μM Aβ1-42 incubated with 5 μM CTerm, equimolar to the albumin concentration in the CSF. Reversed-phase chromatography and electron microscopy analysis demonstrated a reduction of Aβ1-42 aggregates when the CTerm was present. Furthermore, we treated a human neuroblastoma cell line with soluble and aggregated Aβ1-42 incubated with CTerm obtaining a significant protection against Aβ-induced neurotoxicity. These in silico and in vitro data suggest that the albumin CTerm is able to impair Aβ aggregation and to promote disassemble of Aβ aggregates protecting neurons., This work was supported by the Spanish Ministry of Economy and Business through grant Plan Estatal SAF2017-83372-R & SAF2014-52228-R (FEDER funds/UE) to FJM and RV; BIO2017-85329-R to BO; AGL2014-52395-C2 and AGL2017- 84097-C2-2-R to D.A.; MDM-2014-0370 through the “María de Maeztu” Programme for Units of Excellence in R&D to “Departament de Ciències Experimentals i de la Salut”; the Chilean Government through Fondecyt 11611065 and AFB170005 to AA, and REDES 180084 to AA and FJM; ISGlobal and IBEC are members of the CERCA Programme, Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Immunogenicity of foot-and-mouth disease virus dendrimer peptides: need for a T-cell epitope and ability to elicit heterotypic responses

  • Cañas Arranz, Rodrigo
  • de León, Patricia
  • Defaus, Sira
  • Torres, Elisa
  • Forner, Mar, 1980-
  • Bustos, María J.
  • Andreu Martínez, David
  • Blanco, Esther
  • Sobrino, Francisco
An approach based on a dendrimer display of B- and T-cell epitopes relevant for antibody induction has been shown to be effective as a foot-and-mouth disease (FMD) vaccine. B2T dendrimers combining two copies of the major FMD virus (FMDV) type O B-cell epitope (capsid proteinVP1 (140-158)) covalently linked to a heterotypic T-cell epitope from non-structural protein 3A (21-35), henceforth B2T-3A, has previously been shown to elicit high neutralizing antibody (nAb) titers and IFN-γ-producing cells in both mice and pigs. Here, we provide evidence that the B- and T-cell epitopes need to be tethered to a single molecular platform for successful T-cell help, leading to efficient nAb induction in mice. In addition, mice immunized with a non-covalent mixture of B2T-3A dendrimers containing the B-cell epitopes of FMDV types O and C induced similarly high nAb levels against both serotypes, opening the way for a multivalent vaccine platform against a variety of serologically different FMDVs. These findings are relevant for the design of vaccine strategies based on B- and T-cell epitope combinations., This research was funded by the Spanish Ministry of Science, Innovation and Universities (grants AGL2014-48923-C2 and AGL2017-84097-C2-2-R (to D.A. and F.S), and PID2019-107145RB-100 (to E.B.)), as well as by Comunidad de Madrid co-financed ECFEDER funds (S2013/ABI-350 2906-PLATESA and P2018/BAA-4370 to F.S. and E.B.), and by Generalitat de Catalunya (2009SGR492 to D.A.). Work at Centro de Biología Molecular “Severo Ochoa” and at UPF was supported by the Fundación Ramón Areces and by the Maria de Maeztu Program of the Spanish Ministry of Science, Innovation and Universities, respectively. M.F. and R.C.-A. were holders of a PhD fellowship from the Spanish Ministry of Science, Innovation and Universities.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Effect of the aggregated protein dye YAT2150 on Leishmania parasite viability

  • Román-Álamo, Lucía
  • Avalos-Padilla, Yunuen
  • Bouzón-Arnáiz, Inés
  • Iglesias, Valentin
  • Fernández Lajo, Jorge
  • Monteiro, Juan M.
  • Rivas, Luis
  • Fisa, Roser
  • Riera, Cristina
  • Andreu Martínez, David
  • Pintado-Grima, Carlos
  • Ventura, Salvador
  • Arce, Elsa M.
  • Muñoz-Torrero, Diego
  • Fernàndez Busquets, Xavier
The problems associated with the drugs currently used to treat leishmaniasis, including resistance, toxicity, and the high cost of some formulations, call for the urgent identification of new therapeutic agents with novel modes of action. The aggregated protein dye YAT2150 has been found to be a potent antileishmanial compound, with a half-maximal inhibitory concentration (IC50) of approximately 0.5 µM against promastigote and amastigote stages of Leishmania infantum. The encapsulation in liposomes of YAT2150 significantly improved its in vitro IC50 to 0.37 and 0.19 µM in promastigotes and amastigotes, respectively, and increased the half-maximal cytotoxic concentration in human umbilical vein endothelial cells to >50 µM. YAT2150 became strongly fluorescent when binding intracellular protein deposits in Leishmania cells. This fluorescence pattern aligns with the proposed mode of action of this drug in the malaria parasite Plasmodium falciparum, the inhibition of protein aggregation. In Leishmania major, YAT2150 rapidly reduced ATP levels, suggesting an alternative antileishmanial mechanism. To the best of our knowledge, this first-in-class compound is the only one described so far having significant activity against both Plasmodium and Leishmania, thus being a potential drug for the treatment of co-infections of both parasites., This work was supported by grants (i) Fundació La Marató de TV3, Ref. 201811 (X.F.-B.); (ii) PID2021-128325OB-I00 (X.F.-B.) and PID2020-118127RB-I00 (D.M.-T.), funded by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033), which included ERDF funds; (iii) II Premis Innovació Campus Clínic 2022, Hospital Clínic de Barcelona (X.F.-B.); and (iv) Generalitat de Catalunya, Spain (http://agaur.gencat.cat/), grant numbers 2021-SGR-00635 (S.V.) and 2021-SGR-00357 (D.M.-T.). Work at Pompeu Fabra University was supported by “La Caixa” Banking Foundation (https://fundacionlacaixa.org/, grant HR17-00409) and by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D from the Spanish Ministry of Science, Innovation and Universities. Work at the Centro de Investigaciones Biológicas was supported by grants from MCIN Subdirección General de Redes y Centros de Investigación Cooperativa-FEDER RD16/0027/0010 and CSIC PIE 201620E038. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Peptide-based vaccines: foot-and-mouth disease virus, a paradigm in animal health

  • Forner, Mar, 1980-
  • Cañas Arranz, Rodrigo
  • Defaus, Sira
  • de León, Patricia
  • Rodríguez Pulido, Miguel
  • Ganges, Lliliane
  • Blanco, Esther
  • Sobrino, Francisco
  • Andreu Martínez, David
Vaccines are considered one of the greatest global health achievements, improving the welfare of society by saving lives and substantially reducing the burden of infectious diseases. However, few vaccines are fully effective, for reasons ranging from intrinsic limitations to more contingent shortcomings related, e.g., to cold chain transport, handling and storage. In this context, subunit vaccines where the essential antigenic traits (but not the entire pathogen) are presented in rationally designed fashion have emerged as an attractive alternative to conventional ones. In particular, this includes the option of fully synthetic peptide vaccines able to mimic well-defined B- and T-cell epitopes from the infectious agent and to induce protection against it. Although, in general, linear peptides have been associated to low immunogenicity and partial protection, there are several strategies to address such issues. In this review, we report the progress towards the development of peptide-based vaccines against foot-and-mouth disease (FMD) a highly transmissible, economically devastating animal disease. Starting from preliminary experiments using single linear B-cell epitopes, recent research has led to more complex and successful second-generation vaccines featuring peptide dendrimers containing multiple copies of B- and T-cell epitopes against FMD virus or classical swine fever virus (CSFV). The usefulness of this strategy to prevent other animal and human diseases is discussed., This research was funded by the European Commission (project H2020-FETOPEN-2018-2019-2020-01 n° 828774), by the Spanish Ministry of Science, Innovation and Universities, grants AGL2014-48923-C2 and AGL2017-84097-C2-2-R (to D.A. and F.S.), and AGL2016-349 76445-R (to E.B.), as well as by Comunidad de Madrid co-financed ECFEDER funds (S2013/ABI-350 2906-PLATESA and P2018/BAA-4370 to F.S. and E.B.), and by Generalitat de Catalunya (2009SGR492 to D.A.). Work at Centro de Biología Molecular “Severo Ochoa” and at UPF was supported by Fundación Ramón Areces and by the Maria de Maeztu Program of the Spanish Ministry of Science, Innovation and Universities, respectively. M.F. and R.C.-A. were holders of a PhD fellowship from the Spanish Ministry of Science, Innovation and Universities.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The protein aggregation inhibitor YAT2150 has potent antimalarial activity in Plasmodium falciparum in vitro cultures

  • Bouzón-Arnáiz, Inés
  • Avalos-Padilla, Yunuen
  • Biosca, Arnau
  • Caño-Prades, Omar
  • Román-Álamo, Lucía
  • Valle, Javier
  • Andreu Martínez, David
  • Moita, Diana
  • Prudêncio, Miguel
  • Arce, Elsa M.
  • Muñoz-Torrero, Diego
  • Fernàndez Busquets, Xavier
Background: By 2016, signs of emergence of Plasmodium falciparum resistance to artemisinin and partner drugs were detected in the Greater Mekong Subregion. Recently, the independent evolution of artemisinin resistance has also been reported in Africa and South America. This alarming scenario calls for the urgent development of new antimalarials with novel modes of action. We investigated the interference with protein aggregation, which is potentially toxic for the cell and occurs abundantly in all Plasmodium stages, as a hitherto unexplored drug target in the pathogen. Results: Attempts to exacerbate the P. falciparum proteome's propensity to aggregation by delivering endogenous aggregative peptides to in vitro cultures of this parasite did not significantly affect their growth. In contrast, protein aggregation inhibitors clearly reduced the pathogen's viability. One such compound, the bis(styrylpyridinium) salt YAT2150, exhibited potent antiplasmodial activity with an in vitro IC50 of 90 nM for chloroquine- and artemisinin-resistant lines, arresting asexual blood parasites at the trophozoite stage, as well as interfering with the development of both sexual and hepatic forms of Plasmodium. At its IC50, this compound is a powerful inhibitor of the aggregation of the model amyloid β peptide fragment 1-40, and it reduces the amount of aggregated proteins in P. falciparum cultures, suggesting that the underlying antimalarial mechanism consists in a generalized impairment of proteostasis in the pathogen. YAT2150 has an easy, rapid, and inexpensive synthesis, and because it fluoresces when it accumulates in its main localization in the Plasmodium cytosol, it is a theranostic agent. Conclusions: Inhibiting protein aggregation in Plasmodium significantly reduces the parasite's viability in vitro. Since YAT2150 belongs to a novel structural class of antiplasmodials with a mode of action that potentially targets multiple gene products, rapid evolution of resistance to this drug is unlikely to occur, making it a promising compound for the post-artemisinin era., This work was supported by grants (i) PCIN-2017-100, RTI2018-094579-B-I00 and PID2021-128325OB-I00 (XF-B), and SAF2017-82771-R and PID2020-118127RB-I00 (DM-T), funded by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033 for grants PID2021- and PID2020-), which for grants RTI2018-, PID2021-, and SAF2017- included FEDER funds; (ii) ERA-NET Cofund EURONANOMED (http://euronanomed.net/), grant number 2017-178 (XF-B); and (iii) Generalitat de Catalunya, Spain (http://agaur.gencat.cat/), grant numbers 2017-SGR-908 (XF-B) and 2017-SGR-106 (DM-T). Work at Pompeu Fabra University was supported by the “La Caixa” Banking Foundation (https://fundacionlacaixa.org/, grant HR17-00409), and by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D from the Spanish Ministry of Science, Innovation and Universities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A2A receptor homodimer-disrupting sequence efficiently delivered by a protease-resistant, cyclic CPP vector

  • Gallo, María, 1989-
  • Navarro, Gemma
  • Franco, Rafael
  • Andreu Martínez, David
G-protein-coupled receptors associate into dimers/oligomers whose function is not well understood. One approach to investigate this issue is to challenge oligomerization by peptides replicating transmembrane domains and to study their effect on receptor functionality. The disruptor peptides are typically delivered by means of cell-penetrating vectors such as the human immunodeficiency virus (HIV) transcription trans-activation protein Tat. In this paper we report a cyclic, Tat-like peptide that significantly improves its linear analogue in targeting interreceptor sequences in the transmembrane space. The same cyclic Tat-like vector fused to a transmembrane region not involved in receptor oligomerization was totally ineffective. Besides higher efficacy, the cyclic version has enhanced proteolytic stability, as shown by trypsin digestion experiments., Work at Pompeu Fabra University supported by grants AGL2014-52395-C2 and AGL2017-84097-C2-2-R and by the “María de Maeztu” Program for Units of Excellence in R&D from the Spanish Ministry of Innovation and Competitiveness (MINECO). Work at University of Barcelona supported by grants from the U.S. Alzheimer’s Association (AARFD-17-503612), from MINECO (BFU2015-64405-R; it may include EU FEDER funds) and from the Spanish Ministry of Science, Innovation and Universities and Agencia Estatal de Investigación (#2019_RTI2018-094204-B-I00; it includes EU FEDER funds).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Examining topoisomers of a snake-venom-derived peptide for improved antimicrobial and antitumoral properties

  • Carrera-Aubesart, Adam
  • Defaus, Sira
  • Pérez-Peinado, Clara, 1991-
  • Sandín, Daniel
  • Torrent Burgas, Marc
  • Jiménez, M. Ángeles
  • Andreu Martínez, David
Ctn[15-34], the C-terminal section of crotalicidin (Ctn), a cathelicidin from a South American pit viper, is an antimicrobial and antitumoral peptide with remarkably longer stability in human serum than the parent Ctn. In this work, a set of topoisomers of both Ctn and Ctn[15-34], including the retro, enantio, and retroenantio versions, were synthesized and tested to investigate the structural requirements for activity. All topoisomers were as active as the cognate sequences against Gram-negative bacteria and tumor cells while slightly more toxic towards normal cells. More importantly, the enhanced serum stability of the D-amino-acid-containing versions suggests that such topoisomers must be preferentially considered as future antimicrobial and anticancer peptide leads., Financial support from the Spanish Ministry of Economy and Innovation (grant AGL2017-84097-C2-2-R), from the Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033 grants PID2020-113184RB-C22; PID2020-112821GB-I00 and PID2020-114627RB-I00; MCIN/AEI/10.13039/501100011033/FEDER PDC2021-121544-I00), from the EU (Next GenerationEU/PRTR) and from La Caixa Banking Foundation (HR17-00409) is acknowledged.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Human Albumin Impairs Amyloid β-peptide Fibrillation Through its C-terminus, From docking Modeling to Protection Against Neurotoxicity in Alzheimer's disease

  • Picón-Pagès, Pol
  • Bonet, Jaume
  • García-García, Javier
  • Garcia-Buendia, Joan
  • Gutiérrez, Daniela
  • Valle García, Javier|||0000-0002-6787-8286
  • Gómez-Casuso, Carmen E. S.
  • Sidelkivska, Valeriya
  • Alvarez, Alejandra
  • Peralvarez-Marin, Alex|||0000-0002-3457-0875
  • Suades, Albert
  • Fernández Busquets, Xavier|||0000-0002-4622-9631
  • Andreu Martínez, David|||0000-0002-6317-6666
  • Vicente, Rubén|||0000-0003-0401-4808
  • Oliva Miguel, Baldomero|||0000-0003-0702-0250
  • Muñoz, Francisco J.
Alzheimer's disease (AD) is a neurodegenerative process characterized by the accumulation of extracellular deposits of amyloid β-peptide (Aβ), which induces neuronal death. Monomeric Aβ is not toxic but tends to aggregate into β-sheets that are neurotoxic. Therefore to prevent or delay AD onset and progression one of the main therapeutic approaches would be to impair Aβ assembly into oligomers and fibrils and to promote disaggregation of the preformed aggregate. Albumin is the most abundant protein in the cerebrospinal fluid and it was reported to bind Aβ impeding its aggregation. In a previous work we identified a 35-residue sequence of clusterin, a well-known protein that binds Aβ, that is highly similar to the C-terminus (CTerm) of albumin. In this work, the docking experiments show that the average binding free energy of the CTerm-Aβ simulations was significantly lower than that of the clusterin-Aβ binding, highlighting the possibility that the CTerm retains albumin's binding properties. To validate this observation, we performed in vitro structural analysis of soluble and aggregated 1 μM Aβ incubated with 5 μM CTerm, equimolar to the albumin concentration in the CSF. Reversed-phase chromatography and electron microscopy analysis demonstrated a reduction of Aβ aggregates when the CTerm was present. Furthermore, we treated a human neuroblastoma cell line with soluble and aggregated Aβ incubated with CTerm obtaining a significant protection against Aβ-induced neurotoxicity. These in silico and in vitro data suggest that the albumin CTerm is able to impair Aβ aggregation and to promote disassemble of Aβ aggregates protecting neurons.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rationally Modified Antimicrobial Peptides from the N-Terminal Domain of Human RNase 3 Show Exceptional Serum Stability

  • Sandín, Daniel|||0000-0002-2805-0208
  • Valle García, Javier|||0000-0002-6787-8286
  • Chaves-Arquero, Belén
  • Prats-Ejarque, Guillem|||0000-0002-8213-4947
  • Larrosa, María Nieves|||0000-0001-8808-0233
  • González-López, Juanjo|||0000-0003-2419-5909
  • Jiménez, María Ángeles|||0000-0001-6835-5850
  • Boix, Ester|||0000-0003-1790-2142
  • Andreu Martínez, David|||0000-0002-6317-6666
  • Torrent, Marc|||0000-0001-6567-3474
Multidrug resistance against conventional antibiotics poses an important threat to human health. In this context, antimicrobial peptides (AMPs) have been extensively studied for their antibacterial activity and promising results have been shown so far. However, AMPs tend to be rather vulnerable to protease degradation, which offsets their therapeutic appeal. Here, we demonstrate how replacing functional residues in the antimicrobial region of human RNase 3-also named eosinophil cationic protein-by non-natural amino acids increases stability in human serum. These changes were also shown to reduce the hemolytic effect of the peptides in general terms, whereas the antimicrobial activity was reasonably preserved. Digestion profiles enabled us to design new peptides with superior stability and lower toxicity that could become relevant candidates to reach clinical stages.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Examining Topoisomers of a Snake-Venom-Derived Peptide for Improved Antimicrobial and Antitumoral Properties

  • Carrera-Aubesart, Adam|||0000-0001-6196-1647
  • Defaus, Sira|||0000-0002-3106-458X
  • Pérez-Peinado, Clara
  • Sandín, Daniel|||0000-0002-2805-0208
  • Torrent, Marc|||0000-0001-6567-3474
  • Jiménez, María Ángeles|||0000-0001-6835-5850
  • Andreu Martínez, David|||0000-0002-6317-6666
Ctn[15-34], the C-terminal section of crotalicidin (Ctn), a cathelicidin from a South American pit viper, is an antimicrobial and antitumoral peptide with remarkably longer stability in human serum than the parent Ctn. In this work, a set of topoisomers of both Ctn and Ctn[15-34], including the retro, enantio, and retroenantio versions, were synthesized and tested to investigate the structural requirements for activity. All topoisomers were as active as the cognate sequences against Gram-negative bacteria and tumor cells while slightly more toxic towards normal cells. More importantly, the enhanced serum stability of the D-amino-acid-containing versions suggests that such topoisomers must be preferentially considered as future antimicrobial and anticancer peptide leads.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Antimicrobial Peptides Can Generate Tolerance by Lag and Interfere with Antimicrobial Therapy

  • Sandín, Daniel|||0000-0002-2805-0208
  • Valle García, Javier|||0000-0002-6787-8286
  • Morata, Jordi|||0000-0002-6146-4322
  • Andreu Martínez, David|||0000-0002-6317-6666
  • Torrent, Marc|||0000-0001-6567-3474
Antimicrobial peptides (AMPs) are widely distributed molecules secreted mostly by cells of the innate immune system to prevent bacterial proliferation at the site of infection. As with classic antibiotics, continued treatment with AMPs can create resistance in bacteria. However, whether AMPs can generate tolerance as an intermediate stage towards resistance is not known. Here, we show that the treatment of Escherichia coli with different AMPs induces tolerance by lag, particularly for those peptides that have internal targets. This tolerance can be detected as different morphological and physiological changes, which depend on the type of peptide molecule the bacterium has been exposed to. In addition, we show that AMP tolerance can also affect antibiotic treatment. The genomic sequencing of AMP-tolerant strains shows that different mutations alter membrane composition, DNA replication, and translation. Some of these mutations have also been observed in antibiotic-resistant strains, suggesting that AMP tolerance could be a relevant step in the development of antibiotic resistance. Monitoring AMP tolerance is relevant vis-á-vis the eventual therapeutic use of AMPs and because cross-tolerance might favor the emergence of resistance against conventional antibiotic treatments.